Flutamide is reported to be rapidly and completely absorbed from the gastrointestinal tract with peak plasma concentrations occurring 1 hour after a dose. It is rapidly and extensively metabolised; the major metabolite (2-hydroxyflutamide) possesses anti-androgenic properties. The half-life of the metabolite is about 6 hours. Both flutamide and 2-hydroxyflutamide are more than 90% bound to plasma proteins. Excretion is predominantly in the urine with only minor amounts appearing in the faeces.
Flutamide is a nonsteroidal ‘pure’ antiandrogen since it has no toher hormonal activity. It acts directly on the target tissues either by blocking androgen uptake or by inhibiting cytoplasmic and nuclear binding cf androgen. In animal studies flutamide reduced prostate and seminal vesicle weights and prevented androgen-stimulated hypertrophy of accessory sex tissues.
Effect & Precaution
Nausea, epigastric distress, vomiting diarhoea, gynaecomastia, galactorhoea, gynaecomastia, galactorhoea, hepatitis, breast tenderness, insomnia.
Precaution: Liver function tests to be done perodically. Water retention may occur in cardiac disease. Water retention may occur in cardiac disease. Long term administration.
Pregnancy: Use with caution.
Breast Feeding: Use with caution.
Man: Use with Caution.